Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms

Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, Takuto Mori, June Takeda, Hirokazu Tozaki, Yoshihiko Satoh, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa

Blood (2022) 140 (Supplement 1): 489–490.

https://doi.org/10.1182/blood-2022-159338

Published: 2022

Journal Articles

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

Hisayuki Yokoyama, Koji Ando, Noriko Fukuhara, Hiroatsu Iida, Suguru Fukuhara, Hiroshi Miyake, Yasushi Tanoue, Maki Yamamoto, Hirokazu Tozaki, Akio Mizutani, Daisuke Morishita, Kunihiko Takeyama, Toshio Shimizu, Noboru Yamamoto

Blood (2022) 140 (Supplement 1): 6211–6212.

https://doi.org/10.1182/blood-2022-157241

Published: 2022

Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, Daisuke Morishita, Yotaro Ochi, Akio Mizutani, June Takeda, Hirokazu Tozaki, Yoshihiko Satoh, Yasuhito Nannya, Hideki Makishima, Hiroshi Miyake, Seishi Ogawa

Blood (2021) 138 (Supplement 1): 205.

https://doi.org/10.1182/blood-2021-148205

Published: 2021

Journal Articles

Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas

Daisuke Morishita, PhD, Akio Mizutani, PhD, Hirokazu Tozaki, PhD, Yasuyoshi Arikawa, PhD, Takuro Kameda, MD PhD, Ayako Kamiunten, MD, Keisuke Kataoka, MD PhD, Akinori Yoda, PhD, Yotaro Ochi, MD, Kotaro Shide, MD PhD, Koji Izutsu, MD PhD, Yosuke Minami, MDPhD, Kazuya Shimoda, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD

Blood (2020) 136 (Supplement 1): 3–4.

https://doi.org/10.1182/blood-2020-141824

Published: 2020

Journal Articles

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Akinori Yoda, PhD, Daisuke Morishita, PhD, Akio Mizutani, PhD, Yoshihiko Satoh, PhD, Yotaro Ochi, MD, Yasuhito Nannya, MD PhD, Hideki Makishima, MD PhD, Hiroshi Miyake, PhD, Seishi Ogawa, MD PhD

Blood (2019) 134 (Supplement_1): 404.

https://doi.org/10.1182/blood-2019-131559

Published: 2019

NARROW

CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Email alerts

ASH Publications

American Society of Hematology

CTX-712, a Novel Splicing Modulator Targeting Myeloid Neoplasms

A First-in-Human Phase I Study of CTX-712 in Patients with Advanced, Relapsed or Refractory Malignant Tumors - Hematologic Malignancies Dose Escalation Cohort

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Preclinical Evaluation of a Novel MALT1 Inhibitor CTX-177 for Relapse/Refractory Lymphomas

CTX-712, a Novel Clk Inhibitor Targeting Myeloid Neoplasms with SRSF2 Mutation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only